Teva Pharmaceutical Industries Limited (FRA:TEV)
Germany · Delayed Price · Currency is EUR | Market Cap | 37.24B +94.4% |
| Revenue (ttm) | 15.16B +4.1% |
| Net Income | 617.96M |
| EPS | 0.53 |
| Shares Out | n/a |
| PE Ratio | 60.26 |
| Forward PE | 12.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105 |
| Open | 31.00 |
| Previous Close | 31.30 |
| Day's Range | 30.70 - 31.30 |
| 52-Week Range | 15.30 - 32.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About FRA:TEV
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?
Teva's three branded therapies of Austedo, Ajovy, and Uzedy brought in $1.1 billion in third-quarter revenue.
What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call
Teva Pharmaceutical Industries NYSE: TEVA reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by ...
Teva (TEVA) Q3 2026 Earnings Call Transcript
Innovative drugs offset generic declines as Teva raises full-year guidance.
Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo
Teva Pharmaceutical Industries expects to grow in 2027 despite the US inflation reduction act that will cap prices for its top branded drug Austedo to treat Huntington's Disease and Tardive Dyski...
Teva Pharmaceutical Industries Limited Reports Q3 2026 Financial Results and Raises 2026 Outlook for Key Innovative Brands
Teva Pharmaceutical Industries Limited reported Q3 2026 revenues of $4.4 billion, a decrease of 2% year-over-year in both U.S. dollars and local currency terms. This decrease primarily reflected lower...
Teva Pharma Jumps As Top 6% Pharma Raises Outlook After Quarterly Beat
Teva stock advanced early Tuesday on better-than-expected third-quarter metrics and a raised outlook for 2026.
Teva Pharmaceutical Industries Earnings Call Transcript: Q3 2026
Q3 revenue fell 2%, while non-GAAP EPS rose 10% and innovative brands grew strongly. FY 2026 guidance increased, and investment-grade ratings and debt reduction support the growth and pipeline investment plan.
Teva Pharmaceutical Industries Slides: Q3 2026
Teva Pharmaceutical Industries has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Teva Pharmaceutical Industries Earnings release: Q3 2026
Teva Pharmaceutical Industries released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Teva Pharmaceutical Industries Quarterly report: Q3 2026
Teva Pharmaceutical Industries has published its Q3 2026 quarterly earnings report on November 3, 2026.
Teva Pharmaceutical Q3 profit gain beats estimates
Israeli drugmaker Teva Pharmaceutical Industries, reported on Tuesday a higher-than-expected rise in third-quarter profit, helped by strong sales of a trio of its own drugs to offset declines in c...
Teva Expands Biosimilars Portfolio Through New Samsung Bioepis Agreement
(RTTNews) - Teva Pharmaceutical Industries (TEVA) and Samsung Bioepis have entered into a licensing and commercialization agreement that will give Teva U.S. commercialization right to two FDA-approved...
Teva To Obtain U.S. Commercialization Rights For Two FDA-approved Immunology Biosimilars
(RTTNews) - Teva Pharmaceutical Industries (TEVA) and Samsung Bioepis have entered into a license and commercialization agreement for two FDA-approved immunology biosimilars: infliximab-abda, a biosim...
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027 Collaboration combines Samsung Bioepis' biosimilar expertise with Teva's...
Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Increased by 35.74% to $0.15
The average one-year price target for Teva Pharmaceutical Industries Limited - Depositary Receipt (NYSE:TEVA) has been revised to $0.15 / share. This is an increase of 35.74% from the prior estimate o...
Teva To Discontinue TOPAS-MSA Study In Adults With Multiple System Atrophy
(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced that it will discontinue the Phase 2 TOPAS-MSA study evaluating emrusolmin or TEV-286 in adults w...
Teva to discontinue mid-stage neurodegenerative disorder study
Teva said on Monday it was discontinuing its mid-stage neurodegenerative disorder study due to a low probability of the study meeting its main goal if continued.
Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?
Teva's pivot from generics to branded drugs has succeeded, but keep an eye out for this potential headwind.
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review
SPDW, SPOT, TEVA, SE: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) w...
Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Decreased by 19.30% to $0.11
The average one-year price target for Teva Pharmaceutical Industries Limited - Depositary Receipt (NYSE:TEVA) has been revised to $0.11 / share from $0.13 on October 1, 2026, a decrease of 19.30%. The...
Teva, Sanofi Report Sustained Duvakitug Benefits In Phase 2b IBD Study
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) announced positive long-term Phase 2b data for investigational duvakitug, showing sustained improvements in ulcerative colitis (...
Mayne Pharma Agrees To Settle IMVEXXY Patent Litigation With Teva Pharmaceutical
(RTTNews) - On Friday, Mayne Pharma Group Ltd., (MYX.AX) said it has agreed to settle U.S. patent litigation with Teva Pharmaceuticals USA (TEVA) concerning IMVEXXY, its estradiol vaginal inserts for ...
Noteworthy ETF Inflows: EFA, SPOT, TEVA, SE
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI EAFE ETF (Symbol: EFA) where we have detected an approxim...
Teva to Host R&D Day on Wednesday, November 11 in New York City
TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D D...